Tigatuzumab

{
  "id": "MLC-T-ONC-017161",
  "term": "Tigatuzumab",
  "field": "Oncology and biomedicine",
  "definition": "A humanized agonistic monoclonal antibody directed against human tumor necrosis factor-related apoptosis-inducing ligand receptor 2 (TRAIL-R2) with potential antitumor activity. Mimicking the natural receptor ligand TRAIL, tigatuzumab binds to TRAIL-R2, activating signal transduction pathways that may result in tumor cell apoptosis and a reduction in tumor growth. A member of the tumor necrosis factor (TNF) receptor family, TRAIL-R2, also known as DR5 (death receptor 5), is expressed on the surfaces of many types of malignant cells.",
  "synonyms": [
    "Anti-DR5 MoAb",
    "Anti-TRAIL-R2 MoAb"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/tigatuzumab/"
}